Trial · NCT02287818

A Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Gout

NCT02287818, Phase 2, Completed, TWi Biotechnology, Inc.; results first posted 2020-10-28

3 sourcestrials-2026-11-12-0.4.0

Cite this record

ConductScience Library. A Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Gout. Trials, record NCT02287818. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02287818

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: A Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Gout
NCT number: NCT02287818
Status: Completed
Phases: Phase 2
Enrollment: 127 participants, actual
Lead sponsor: TWi Biotechnology, Inc.
Conditions: Gout
Interventions: Placebo, AC-201, Febuxostat
First posted: 2014-11-11
Last updated: 2022-06-28
Results first posted: 2020-10-28

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Proportion of Subjects Achieving Serum Uric Acid Concentration <6.0 mg/dL	8 weeks

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Proportion of Subjects Achieving Serum Uric Acid Concentration <6.0 mg/dL	8 weeks		Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group2

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Proportion of Subjects Achieving Serum Uric Acid Concentration <6.0 mg/dL	Placebo		33		Participants
Proportion of Subjects Achieving Serum Uric Acid Concentration <6.0 mg/dL	AC-201		43		Participants

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo	60
Overall Study	STARTED	AC-201	67
Overall Study	COMPLETED	Placebo	53
Overall Study	COMPLETED	AC-201	54
Overall Study	NOT COMPLETED	Placebo	7
Overall Study	NOT COMPLETED	AC-201	13

Source ClinicalTrials.gov

Adverse events34

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Blood and lymphatic system disorders	Blood and lymphatic system disorders	Placebo	1	60
other	Blood and lymphatic system disorders	Blood and lymphatic system disorders	AC-201	0	67
other	Cardiac disorders	Cardiac disorders	Placebo	1	60
other	Cardiac disorders	Cardiac disorders	AC-201	0	67
other	Gastrointestinal disorders	Gastrointestinal disorders	Placebo	7	60
other	Gastrointestinal disorders	Gastrointestinal disorders	AC-201	25	67
other	General disorders and administration site	General disorders	Placebo	1	60
other	General disorders and administration site	General disorders	AC-201	1	67
other	Hepatobiliary disorders	Hepatobiliary disorders	Placebo	1	60
other	Hepatobiliary disorders	Hepatobiliary disorders	AC-201	2	67

1 to 10 of 34Source ClinicalTrials.gov

See all 34 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Placebo	0	60
Total, all-cause mortality	AC-201	0	67
Total, other adverse events	Placebo	29	60
Total, other adverse events	AC-201	43	67
Total, serious adverse events	Placebo	0	60
Total, serious adverse events	AC-201	0	67

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons3

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
AC-201 vs Placebo: Proportion of Subjects Achieving Serum Uric Acid Concentration <6.0 mg/dL	Trial comparisons
AC-201 vs Placebo: deaths from any cause	Trial comparisons
AC-201 vs Placebo: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Source

Release: trials-2026-11-12-0.4.0
Release manifest SHA-256: 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
Registry capture: 2026-11-12
Results copy, AACT: 2026-03-23
NIH clinical studies file: 2026-11-13

Source ClinicalTrials.gov

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNone stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02287818

GET https://conductscience.org/api/trials/v1/NCT02287818/events?page=2

API reference For AI assistants